Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionJacobs Levy Equity Management, Inc
Latest Disclosed Ownership520,269 shares
Latest Disclosed Value $ 68,540,238
Jacobs Levy Equity Management, Inc reports 1,389.63% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 15, 2026 - Jacobs Levy Equity Management, Inc filed a 13F-HR form disclosing ownership of 520,269 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $68,540,238 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 34,926 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 1,389.63% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 520,269 485,343 1,389.63 68,540 1,283.81 0.2881
2026-02-13 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 34,926 -594 -1.67 4,954 -0.66 0.0191
2025-11-17 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 35,520 -18,480 -34.22 4,986 -26.54 0.0198
2025-08-14 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 54,000 -34,915 -39.27 6,787 -30.98 0.0266
2025-05-15 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 88,915 21,726 32.34 9,834 7.22 0.0390
2025-02-14 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 67,189 -456,979 -87.18 9,171 -84.81 0.0324
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 524,168 -196,919 -27.31 60,395 -39.16 0.2329
2024-08-14 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 721,087 8,289 1.16 99,272 0.98 0.4105
2024-05-15 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 712,798 -40,067 -5.32 98,309 -0.90 0.4393
2024-02-14 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 752,865 60,491 8.74 99,197 27.35 0.4998
2023-11-17 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 692,374 256,920 59.00 77,892 89.69 0.4614
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 435,454 4,118 0.95 41,063 -5.95 0.2367
2023-05-15 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 431,336 367,229 572.84 43,660 470.26 0.2676
2023-02-14 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 64,107 50,540 372.52 7,657 431.30 0.0518
2022-11-15 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,567 13,567 1,441 0.0114
2021-05-17 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -6,308 -100.00 0 -100.00
2021-02-16 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,308 -25,173 -79.96 605 -80.01 0.0053
2020-11-16 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 31,481 3,947 14.34 3,027 -9.88 0.0314
2020-08-17 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 27,534 -122,910 -81.70 3,359 -74.20 0.0364
2020-05-15 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 150,444 -11,388 -7.04 13,021 -25.15 0.1673
2020-02-14 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 161,832 47,903 42.05 17,395 69.44 0.1707
2019-11-14 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 113,929 -20,450 -15.22 10,266 -9.52 0.1260
2019-08-13 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 134,379 50,210 59.65 11,346 53.01 0.1570
2019-05-14 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 84,169 84,169 7,415 0.1070
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.